Anti-PD-1 (Opdivo) (Nivolumab biosimilar) mAb

Nivolumab (Optivo), Pembrolizumab are both PD-1 inhibitors. PD-1 is a checkpoint" protein on immune cells that alerts them not to attack cells that express PD-L1. Some cancer cells express PD-L1, which enables them to “switch off” an immune system response. Monoclonal antibodies such as pembrolizumab and nivolumab block this signaling between PD-1 and PD-L1 and thereby reinforce the immune system response to tumor cells.